Medicare Enrolled

Dr. Geoffrey Oxnard, MD

Medical Oncology · Boston, MA
830 HARRISON AVE, Boston, MA 02118
6176386428
Registered in NPPES since 2007
NPI: 1033300157 verify on NPPES ↗
High
DATA COVERAGE
Data in 3 of 4 federal sources
Measures public federal data availability — not provider quality
Informational, not a quality rating. This page presents federal public records about Dr. Oxnard from CMS (NPPES, Open Payments, Medicare Provider Utilization, PECOS). It is not medical advice, an endorsement, or a judgment of clinical quality. Always consult the provider directly and a licensed clinician for medical decisions. Read methodology →
Are you Dr. Oxnard? Request a correction or review of any data shown here. Provider portal →

What this data tells you about Dr. Oxnard

Dr. Geoffrey Oxnard is a medical oncology specialist in Boston, MA, with 19 years of NPI registration.

Between the years covered by Open Payments, Dr. Oxnard received a total of $44,941 from 13 pharmaceutical and/or device companies across 40 payment records. A record can group multiple payments. These transfers are publicly reported through CMS Open Payments. Disclosure alone does not establish their effect on care. A reliable breakdown by payment category is not available in this snapshot. Patients may wish to discuss these relationships with their provider.

The Data Coverage level for Dr. Oxnard is High — reflecting how much public federal data is available about this provider. Patients are encouraged to use this data as one of several factors when choosing a healthcare provider.

✓ 19 years of NPI registration $44,941 industry payments

Industry Payment Transparency

Open Payments through 2020 ↗
$44,941
Total received (2018-2020)
Avg $14,980/year across 3 years
Top 27% in MA for medical oncology
A higher payment rank reflects disclosed industry relationships (consulting, research, speaking) common among subspecialists — not wrongdoing.
13
Companies
40
Payment records
Payments are publicly reported; disclosure does not establish legality · Not evidence of wrongdoing · How to interpret →

Payment categories are unavailable while the source breakdown is being rebuilt. Company and year totals do not identify how much belongs to each category.

Payment trend by year

Annual totals from pharmaceutical and medical device companies.

2020
$16,103
2019
$17,781
2018
$11,057

Payments by company (2020)

AstraZeneca Pharmaceuticals LP
$8,345
Takeda Pharmaceuticals U.S.A., Inc.
$3,418
AstraZeneca UK Limited
$2,740
AbbVie Inc.
$1,100
Merck Sharp & Dohme Corporation
$500
Top 3 companies account for 90.1% of 2020 payments
All-time payments by company (2018-2020) ›
AstraZeneca Pharmaceuticals LP
$22,587
Boehringer Ingelheim International GmbH
$6,784
AstraZeneca UK Limited
$5,248
Takeda Pharmaceuticals U.S.A., Inc.
$3,418
Janssen Global Services, LLC
$1,550
PFIZER INC.
$1,270
AbbVie Inc.
$1,100
Foundation Medicine, Inc.
$1,000
Sysmex Inostics Inc
$750
F. Hoffmann-La Roche AG
$577
Merck Sharp & Dohme Corporation
$500
Eli Lilly and Company
$148
Genentech USA, Inc.
$9
Top 3 companies account for 77.0% of all-time payments
Associated products mentioned in payments ›
Alecensa · FOUNDATIONONE LIQUID · GILOTRIF · IMFINZI · KEYTRUDA · LORBRENA · TAGRISSO
Should you be concerned? Industry payments are disclosed through CMS Open Payments. Disclosure alone does not establish their purpose, legality, or effect on care. What matters is whether a recommended drug or device appears in your doctor's payment records. If so, consider asking your doctor about it. How to interpret this data →
Looking for a medical oncology specialist in Boston?
Compare medical oncologists in the Boston area by procedure volume, costs, and industry payment transparency.
Browse medical oncologists nearby

Geographic Context

Medical oncologists in nearby ZIP areas
233
County median income
$92,859
Nearest hospital to ZIP centroid (approximate)
BOSTON MEDICAL CENTER
0.0 mi

Data Sources

Provider Registry ✓ NPPES NPPES snapshot; verify current record
Medicare Enrollment ✓ PECOS PECOS snapshot
Practice Data — No data N/A
Industry Payments ✓ Open Payments CY 2020
Disciplinary History — Not included N/A

This provider has data in 3 of 4 available federal datasets, with a Data Coverage level of High. This reflects how much public data is available about a provider. How we calculate this →

Summary

Dr. Oxnard is a medical oncology specialist, with 19 years of NPI registration.

This summary is auto-generated from federal data, describing data availability and patterns. Read our methodology →

Frequently Asked Questions

Does Dr. Oxnard receive payments from pharmaceutical companies?
Yes. Dr. Oxnard received a total of $44,941 from 13 companies across 40 payment records. A record can group multiple payments. These transfers are publicly disclosed through CMS Open Payments. Disclosure alone does not establish their legality or effect on care. Patients may wish to ask their doctor about these relationships, especially if a recommended drug or device appears in the payment records.
What does Data Coverage mean?
Data Coverage (currently High for Dr. Oxnard) measures how much public federal data is available about a provider. It is not a quality rating. A "Very High" or "High" level means the provider has data across multiple federal sources (NPPES, PECOS, Medicare Utilization, Open Payments), indicating the presence of registry, enrollment, activity or payment records, not verified experience or clinical quality. A "Low" or "Moderate" level may simply mean the provider is newer, does not see Medicare patients, or has not received any industry payments — none of which are inherently negative. Read our full methodology →
Is this data up to date?
Source publication dates and the snapshots loaded on this site can differ. Rebuilding a page does not refresh its source records. Check the Medicare reporting year and the payment interval shown above; consult the linked official sources for newer releases and current registry details. See our data freshness policy →

Explore related providers

Same specialty & city
Medical Oncologists in Boston
Browse medical oncologists in Boston ranked by procedure volume and transparency data.
Highest volume
Top Medical Oncologists in MA
Medical oncologists ranked by total Medicare services performed statewide.
Industry payments
Pharma Payments to Medical Oncologists in MA
Which MA medical oncologists receive the most from drug and device companies.
By company
AstraZeneca Pharmaceuticals LP Payments to Doctors
See all physicians who received payments from AstraZeneca Pharmaceuticals LP.
By company
Boehringer Ingelheim International GmbH Payments to Doctors
See all physicians who received payments from Boehringer Ingelheim International GmbH.
By company
AstraZeneca UK Limited Payments to Doctors
See all physicians who received payments from AstraZeneca UK Limited.
About this page

This page combines public CMS records with calculated summaries and explanatory procedure labels. These transformations are not verbatim federal records. Sources: NPPES ↗, Open Payments ↗, and PECOS. Publication is mandated by the Physician Payments Sunshine Act (§6002 ACA, 42 U.S.C. §1320a-7h) and the Freedom of Information Act.

This page is not medical advice, an endorsement, a recommendation, or a quality rating. Data Coverage reflects data completeness — how much federal information exists for this provider — not clinical performance, patient outcomes, or quality of care. Always verify information directly with the provider and consult a licensed clinician before making medical decisions.

Provider corrections: Provider portal · Privacy questions: Privacy Policy · Terms: Terms of Use · Methodology: Methodology

Data Disclaimer — Data sourced from the Centers for Medicare & Medicaid Services (CMS): National Plan and Provider Enumeration System (NPPES), Open Payments program, Medicare Provider Utilization and Payment Data, and Provider Enrollment & Certification data (PECOS). Published under the Freedom of Information Act (FOIA). This website is not affiliated with, endorsed by, or authorized by CMS, HHS, or the U.S. Government. Data may contain errors as reported to CMS by providers and reporting entities. Industry payment disclosure alone establishes neither wrongdoing nor legality. Medicare data reflects only patients aged 65+ or those with qualifying disabilities. For corrections, contact CMS directly. This information does not constitute medical advice and should not be used as the sole basis for choosing a healthcare provider. Procedure descriptions use plain language and do not reference CPT® codes, which are copyrighted by the American Medical Association. Full methodology → · Report a data error → · Privacy policy →